153.07
前日終値:
$156.19
開ける:
$155.385
24時間の取引高:
5.60M
Relative Volume:
0.96
時価総額:
$189.80B
収益:
$29.79B
当期純損益:
$9.22B
株価収益率:
20.83
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
+1.75%
1か月 パフォーマンス:
+1.97%
6か月 パフォーマンス:
+11.21%
1年 パフォーマンス:
+24.64%
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences Inc
|
153.07 | 189.80B | 29.79B | 9.22B | 10.23B | 7.3494 |
|
LLY
Lilly Eli Co
|
1,240.34 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
|
JNJ
Johnson Johnson
|
253.79 | 611.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
|
ABBV
Abbvie Inc
|
282.68 | 499.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
|
MRK
Merck Co Inc
|
143.63 | 354.36B | 65.51B | 8.93B | 14.12B | 3.5532 |
|
NVS
Novartis Ag Adr
|
150.20 | 285.49B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-07-06 | アップグレード | HSBC Securities | Hold → Buy |
| 2026-05-20 | アップグレード | Maxim Group | Hold → Buy |
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success - Benzinga
What Has Changed About Owning Gilead Stock? - Trefis
Gilead Sciences (GILD) Reports Promising Mid-Stage Trial Results for Emvistegrast in Ulcerative Colitis - GuruFocus
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy - Zacks Investment Research
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy - Yahoo Finance
Gilead's pill succeeds in mid-stage bowel disease trial - Reuters
Gilead bowel drug hits mid-stage trial win (GILD:NASDAQ) - Seeking Alpha
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 - BioSpace
Gilead to present HIV and antiviral research at IDWeek 2026 - Investing.com
Gilead Sciences, Inc. (GISD.XC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 - Business Wire
43 ETFs Add to Gilead Sciences (GILD) on Thursday - Yahoo Finance
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds - STAT
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? - The Motley Fool
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc. - MarketBeat
Under a trading plan, Gilead Sciences (GILD) CFO sells 3,000 shares at $156.22 each. - Stock Titan
Gilead Sciences, Inc. $GILD Shares Sold by Curated Wealth Partners LLC - MarketBeat
Could Gilead Sciences (NASDAQ:GILD) Be in Focus After Wall Street’s Latest Rotation? - Kalkine Media
Gilead Sciences, Inc. $GILD Stock Sold by Assenagon Asset Management S.A. - MarketBeat
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Yahoo Finance
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Zacks Investment Research
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research
Gilead Sciences Inc Stock (GILD) Moved Up by 3.67% on Oct 15: Key Drivers Unveiled - TradingKey
Gilead Sciences (NASDAQ:GILD) Hits New 52-Week HighHere's What Happened - MarketBeat
Gilead Sciences stock hits all-time high at 157.32 USD - Investing.com
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership? - Yahoo Finance
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers - BioSpace
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal - Reuters
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors - Business Wire
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Earnings Preview: What to Expect From Gilead Sciences’ Report - Barchart.com
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research
Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says - Yahoo Finance
Can Gilead (GILD) Stock Continue Rising in 2027? - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
BofA raises Gilead Sciences stock price target on growth outlook By Investing.com - Investing.com India
RBC raised target for Gilead Sciences stock to USD 126.00 - ad-hoc-news.de
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive? - Yahoo Finance
Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales? - Yahoo Finance
Gilead Sciences (GILD) Laps the Stock Market: Here's Why - Zacks Investment Research
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
RBC raises target for Gilead Sciences stock to USD 126.00 - AD HOC NEWS
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Oct 15 '26 |
Sale |
156.22 |
3,000 |
468,660 |
113,684 |
| JOHANNA MERCIER | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| ANDREW DICKINSON | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Oct 01 '26 |
Sale |
147.90 |
15,000 |
2,218,508 |
566,683 |
| ANDREW DICKINSON | Officer |
Sep 15 '26 |
Proposed Sale |
145.29 |
3,000 |
435,870 |
0 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
| Dickinson Andrew D | Chief Financial Officer |
Sep 15 '26 |
Sale |
145.29 |
3,000 |
435,870 |
164,096 |
| JOHANNA MERCIER | Officer |
Sep 15 '26 |
Proposed Sale |
144.22 |
3,000 |
432,646 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Sep 01 '26 |
Sale |
148.64 |
15,000 |
2,229,592 |
577,133 |
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Sale |
148.62 |
18,000 |
2,675,220 |
12,894 |
大文字化:
|
ボリューム (24 時間):